1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Summary
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  02:10 2022-08-10 am EDT
0.0260 AUD   +8.33%
04:10aPatrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

New research: Scientists determine structure of a DNA damage ‘First Responder' protein

03/23/2022 | 12:24am EDT

Scientists at the Sloan Kettering Institute have debunked a 20-year guiding paradigm for how the 9-1-1 clamp - a protein involved in the initiation of DNA repair protein - works by using cryo-electron microscopy to uncover how its protein structures fit together.

In surprise findings, the researchers discovered the mechanism of action used by the 9-1-1 clamp is very different to what they previously believed. These findings could be the key to developing more effective cancer treatments that specifically tackle the DNA repair pathway in cancer cells.

Therapeutics tackling cellular DNA repair responses are an exciting new area of development for cancer treatments, and one that Patrys is exploring with our deoxymab technology.

Read the research study.

Disclaimer

Patrys Limited published this content on 23 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 March 2022 05:23:02 UTC.


© Publicnow 2022
All news about PATRYS LIMITED
04:10aPatrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
07/04Patrys Produces Antibody Drug at Commercial Scale
MT
07/03Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run
CI
06/14Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody
MT
06/03Patrys Secures Grant Funding to Develop Brain Cancer Drug
MT
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
04/14PATRYS : Application for quotation of securities - PAB
PU
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
PU
More news
Financials
Sales 2021 1,34 M 0,93 M 0,93 M
Net income 2021 -4,06 M -2,83 M -2,83 M
Net cash 2021 10,9 M 7,61 M 7,61 M
P/E ratio 2021 -22,2x
Yield 2021 -
Capitalization 49,4 M 34,4 M 34,4 M
EV / Sales 2020 11,5x
EV / Sales 2021 67,8x
Nbr of Employees 10
Free-Float 70,9%
Chart PATRYS LIMITED
Duration : Period :
Patrys Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PATRYS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
James A. Campbell Chief Executive Officer, MD & Director
John Douglas Read Non-Executive Chairman
Valentina Dubljevic Vice President-Scientific & Clinical Development
Michael J. Stork Deputy Chairman & Non-Executive Director
Suzy Jones Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PATRYS LIMITED-35.14%34
MODERNA, INC.-32.62%66 950
LONZA GROUP AG-26.76%43 416
IQVIA HOLDINGS INC.-17.56%43 382
SEAGEN INC.13.58%32 387
ALNYLAM PHARMACEUTICALS, INC.31.72%26 810